Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

NeuBase Therapeutics

NASDAQ NBSE
$0.38 -0.01 -3.31%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 20 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

1.04M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
-21.45M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
-0.13
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
2.76M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-48.93 %

Upcoming events NeuBase Therapeutics

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart NeuBase Therapeutics

Stock analysis NeuBase Therapeutics

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
-0.07 27.46
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
0.04 4.32
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
1.52 9.63
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
1.60 0.64
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
-156.66 7.67

Price change NeuBase Therapeutics per year

3.26$ 12.89$
Min Max

Summary analysis NeuBase Therapeutics

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure NeuBase Therapeutics

Revenue and net income NeuBase Therapeutics

All parameters

Stock news NeuBase Therapeutics

All news
28 June 2023 в 22:10

NeuBase Therapeutics Selling Stock and Issuing Warrants

28 June 2023 в 22:05

NeuBase Therapeutics Selling Stock and Issuing Warrants

21 October 2022 в 14:35

NeuBase Therapeutics downgraded to perform from outperform at Oppenheimer

14 October 2022 в 23:30

NeuBase Therapeutics to Cut Workforce By 60%, Restructure

14 October 2022 в 23:30

NeuBase Therapeutics to Cut Workforce By 60%, Restructure

About company NeuBase Therapeutics

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders and cancer. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; and NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
Address:
700 Technology Drive, Pittsburgh, PA, United States, 15219
Company name: NeuBase Therapeutics
Issuer ticker: NBSE
ISIN: US64132K1025
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2007-05-01
Sector: Healthcare
Industry: Biotechnology
Site: https://www.neubasetherapeutics.com

On which stock exchange are NeuBase Therapeutics (NBSE) stocks traded?

NeuBase Therapeutics (NBSE) stocks are traded on NASDAQ.

What is the ticker of NeuBase Therapeutics stocks (NBSE)?

The stock ticker of NeuBase Therapeutics’s stocks or in other words, the code is NBSE. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does NeuBase Therapeutics (NBSE) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, NeuBase Therapeutics (NBSE) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are NeuBase Therapeutics (NBSE) stocks traded?

NeuBase Therapeutics (NBSE) stocks are traded on the NASDAQ exchange in dollars.

What is the price of NeuBase Therapeutics (NBSE) stocks today?

The current price of NeuBase Therapeutics stocks on 14.05.2024 is 0.378 dollars. per share.

What is the dynamics of NeuBase Therapeutics (NBSE) stocks from the beginning of the year?

NeuBase Therapeutics (NBSE) quotes have increased by -45.62% from the beginning of the year up to 0.378 dollars. per 1 stocks.

How much did NeuBase Therapeutics (NBSE) stocks increase in мае 2024?

This month NeuBase Therapeutics (NBSE) quotes have increased by -9.13% to 0.378 dollars. per share.

How much are NeuBase Therapeutics (NBSE) stocks worth?

Today, on October, 14.05.2024 NeuBase Therapeutics’s (NBSE) stocks cost 0.378 dollars..

What is the market capitalization of NeuBase Therapeutics (NBSE)?

Capitalization is the market value of NeuBase Therapeutics (NBSE) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 14.05.2024, the market capitalization of NeuBase Therapeutics (NBSE) is estimated at about 1042364 dollars.